Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...
Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer. Patients with locally advanced, unresectable (not able ...
Once-a-day use of the targeted cancer pill Tagrisso (osimertinib) cut the five-year death rate in half for a subset of patients with early-stage lung cancer, a new clinical trial shows. The results ...
We are holding firm to our AstraZeneca AZN fair value estimate following clinical updates from the European Society of Medical Oncology (ESMO) annual meeting. Overall, the innovation updates at the ...
AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) ...
Results support potential for a new treatment option that builds on the benefit of first-line standard of care TAGRISSO monotherapy WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results